Novel cyclobutane-containing peptides selectively targeted and killed Leishmania parasites while showing no toxicity to human cells, with drug conjugates active at 1 µM.
2.5× selectivitythese peptides accumulate inside Leishmania parasites 2.5 times more than the well-known TAT cell-penetrating peptide
What the researchers found
Two series of hybrid gamma/gamma-peptides (gamma-CC and gamma-CT) were designed using a chiral cyclobutane amino acid alternating with proline derivatives. Key findings:
Selectivity: both peptide series showed no cytotoxicity to human HeLa cells and only moderate uptake by these cells. In contrast, both 14-mer versions were microbicidal against Leishmania at concentrations above 25 micromolar, with significant intracellular accumulation in the parasite.
Drug delivery: when conjugated to fluorescent doxorubicin (Dox), the peptides showed toxicity to Leishmania above 1 micromolar, while free Dox at the same concentration was not toxic. Intracellular accumulation was 2.5 times higher than with a Dox-TAT conjugate (TAT being the standard cell-penetrating peptide).
Structural insight: computational calculations showed the drug-peptide conjugates fold to bury the Dox moiety inside a cavity while exposing positively charged groups to solvent. This improves Dox solubility and membrane translocation.
Why it matters
Leishmaniasis affects 12 million people and kills 20,000-30,000 annually. Current drugs are toxic and losing effectiveness. A delivery system that selectively targets the parasite while sparing human cells could transform treatment. The 2.5-fold improvement over TAT peptide delivery is significant.
The numbers in context
Non-toxic to HeLa; killing >25µM; Dox conjugate >1µM; 2.5x vs TAT accumulation; 14-mer optimal
How the study worked
Peptide chemistry and parasitology study. Hybrid gamma-peptides were synthesized and tested for cytotoxicity (HeLa cells), parasite killing (Leishmania), and intracellular accumulation. Doxorubicin conjugates were prepared and compared to free Dox and Dox-TAT. Conformational analysis by circular dichroism and molecular dynamics simulations.
Who was studied
HeLa cells and Leishmania parasites (in vitro)
What this study cannot tell us
Tested only in cell culture, not in animal infection models. The selectivity mechanism (why parasites take up the peptide more than human cells) is not fully explained. Only one drug (doxorubicin) was tested as cargo. The 25 micromolar killing concentration for the peptide alone is relatively high. Long-term stability and in vivo biodistribution are unknown.
How to read the evidence
Preliminary evidence from in vitro studies only. Parasite selectivity is promising but animal infection models are needed.
When this study was published
Published in 2020. Peptide-based anti-parasitic strategies continue to be developed for neglected tropical diseases.
The bigger picture
Leishmaniasis affects 12 million people and kills 20,000–30,000 annually. Current drugs are toxic and losing effectiveness. A delivery system that selectively targets the parasite while sparing human cells could transform treatment of this neglected tropical disease.
Questions still open
- Why do parasites accumulate the peptide more than human cells?
- Would this work with other anti-parasitic drugs besides doxorubicin?
- Can these peptides be manufactured affordably for low-income settings?
Common questions
Why is Leishmania so hard to treat?
How do these peptides tell parasites from human cells?
Read the original research
Chiral Cyclobutane-Containing Cell-Penetrating Peptides as Selective Vectors for Anti-Leishmania Drug Delivery Systems.
International journal of molecular sciences, 21(20)
Citation
Illa, Ona; Olivares, José-Antonio; Gaztelumendi, Nerea; Martínez-Castro, Laura; Ospina, Jimena; Abengozar, María-Ángeles; Sciortino, Giuseppe; Maréchal, Jean-Didier; Nogués, Carme; Royo, Míriam; Rivas, Luis; Ortuño, Rosa M. (2020). Chiral Cyclobutane-Containing Cell-Penetrating Peptides as Selective Vectors for Anti-Leishmania Drug Delivery Systems.. International journal of molecular sciences, 21(20). https://doi.org/10.3390/ijms21207502